Mauna Kea Technologies

Report Publication Announcement • Jan 2, 2017

MAUNA KEA TECHNOLOGIES ANNOUNCES ITS 2017 FINANCIAL CALENDAR

Paris, France and Cambridge, MA, USA, January 2, 2017 – Mauna Kea Technologies (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced today its schedule for the publication of financial information for 2017.

Event	Date *
2016 Fourth-Quarter Sales	January 24, 2017
2016 Full-Year Results	March 23, 2017
2017 First-Quarter Sales	April 25, 2017
Annual General Meeting	May 3, 2017
2017 First-Half Sales	July 25, 2017
2017 First-Half Results	September 20, 2017
2017 Third-Quarter Sales	October 24, 2017

* Subject to modification. Press releases are published after market closes.

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico.

For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies
Benoit Jacheet
CFO
investors@maunakeatech.com

United States Zack Kubow / Lee Roth The Ruth Group 646-536-7020 / 7012 zkubow@theruthgroup.com / lroth@theruthgroup.com

U.S. Media

Christopher Hippolyte The Ruth Group 646-536-7023 chippolyte@theruthgroup.com France and Europe

NewCap - Investor Relations Florent Alba +33 (0)1 44 71 94 94 maunakea@newcap.fr